Advanced searches left 3/3

Investigational New Drug - Europe PMC

Summarized by Plex Scholar
Last Updated: 06 August 2022

* If you want to update the article please login/register

Quality control and therapeutic investigations of mesenchymal stem/stromal cells during investigational new drug application for GvHD administration in China.

About half of GvHD patients were steroid-resistant with a two-year overall survival rate lower than 20%. Notably, pioneering researchers have emphasized the clinical or therapeutic benefits of human umbilical cord-derived mesenchymal stem/stromal cells on GvHD, owing to their unique hematopoietic-supporting and immunomodulatory properties. In addition, the GvHD administration's oversight policy and medical ethics, as well as the concomitant risks and challenges, have been discussed.

Source link: https://europepmc.org/article/MED/35619293

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions